Umb Bank N A Has Lifted By $991,048 Its Amgen (AMGN) Stake; Fibrogen (FGEN) Shorts Up By 19.02%

June 20, 2017 - By Marie Mckinney

Fibrogen Incorporated (NASDAQ:FGEN) had an increase of 19.02% in short interest. FGEN’s SI was 2.35M shares in June as released by FINRA. Its up 19.02% from 1.97 million shares previously. With 482,700 avg volume, 5 days are for Fibrogen Incorporated (NASDAQ:FGEN)’s short sellers to cover FGEN’s short positions. The SI to Fibrogen Incorporated’s float is 4.31%. The stock decreased 0.67% or $0.2 during the last trading session, reaching $29.6. About shares traded. FibroGen Inc (NASDAQ:FGEN) has risen 52.86% since June 20, 2016 and is uptrending. It has outperformed by 36.16% the S&P500.

Umb Bank N A increased Amgen Inc (AMGN) stake by 6.26% reported in 2016Q4 SEC filing. Umb Bank N A acquired 6,788 shares as Amgen Inc (AMGN)’s stock declined 9.68%. The Umb Bank N A holds 115,287 shares with $16.86M value, up from 108,499 last quarter. Amgen Inc now has $120.16B valuation. The stock increased 1.64% or $2.67 during the last trading session, reaching $165.09. About 3 shares traded. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since June 20, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.

Umb Bank N A decreased Ishares 1 (CSJ) stake by 10,971 shares to 135,748 valued at $14.25M in 2016Q4. It also reduced Mcdonalds Corp (NYSE:MCD) stake by 26,425 shares and now owns 99,613 shares. Costco Wholesale Corp (NASDAQ:COST) was reduced too.

Investors sentiment decreased to 1.09 in 2016 Q4. Its down 0.17, from 1.26 in 2016Q3. It fall, as 98 investors sold AMGN shares while 488 reduced holdings. 111 funds opened positions while 527 raised stakes. 561.98 million shares or 1.23% less from 568.98 million shares in 2016Q3 were reported. Laurel Grove Capital Ltd Co reported 0.18% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Cullen Frost Bankers owns 0.3% invested in Amgen, Inc. (NASDAQ:AMGN) for 58,750 shares. Sector Pension Investment Board invested 0.23% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Greystone Inv Ltd Co reported 0.12% in Amgen, Inc. (NASDAQ:AMGN). Vnbtrust National Association invested in 4,053 shares. Bnp Paribas Arbitrage Sa has invested 0.34% in Amgen, Inc. (NASDAQ:AMGN). Integrated Wealth Counsel Limited Liability Corporation reported 127 shares. Brick & Kyle Assocs holds 0.08% or 718 shares in its portfolio. The California-based Wells Fargo And Mn has invested 0.31% in Amgen, Inc. (NASDAQ:AMGN). Woodstock Corporation, a Massachusetts-based fund reported 9,920 shares. Tcw Group Inc holds 72,320 shares. Naples Global Advsr Ltd Com invested in 0.94% or 16,577 shares. Fort Washington Inv Advsrs Inc Oh reported 66,222 shares. 826 are owned by Jefferies Gp Ltd Liability Com. Royal Natl Bank Of Canada holds 0.2% or 2.56M shares.

Since May 24, 2017, it had 0 insider buys, and 2 sales for $1.02 million activity. On Wednesday, May 24 Patton Cynthia M sold $451,164 worth of Amgen, Inc. (NASDAQ:AMGN) or 2,922 shares. On Wednesday, May 31 the insider BALTIMORE DAVID sold $569,541.

Among 19 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Amgen Inc. had 34 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Overweight” rating by Morgan Stanley on Tuesday, December 15. The rating was maintained by Oppenheimer on Monday, June 5 with “Buy”. Wells Fargo initiated the stock with “Market Perform” rating in Friday, December 4 report. The rating was maintained by Citigroup with “Neutral” on Wednesday, September 28. Mizuho initiated the stock with “Buy” rating in Tuesday, November 8 report. The rating was maintained by Argus Research with “Buy” on Monday, February 8. As per Saturday, August 29, the company rating was maintained by Piper Jaffray. Jefferies downgraded the shares of AMGN in report on Wednesday, April 5 to “Hold” rating. As per Friday, July 31, the company rating was maintained by RBC Capital Markets. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report.

Among 3 analysts covering FibroGen Inc (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. FibroGen Inc had 6 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Neutral” rating by Credit Suisse on Thursday, January 21. On Thursday, February 11 the stock rating was upgraded by Credit Suisse to “Outperform”. The rating was initiated by Citigroup with “Buy” on Wednesday, July 29. The stock has “Hold” rating by Lake Street on Wednesday, September 23. The rating was initiated by Citigroup with “Buy” on Friday, December 4.

FibroGen, Inc. is a science-based biopharmaceutical company. The company has market cap of $2.10 billion. The Firm is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. It currently has negative earnings. The Company’s lead product candidate is roxadustat .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: